outsourcing

News

Samsung Biologics agrees $1.81bn takeover of PolyPeptide

Samsung Biologics has agreed to buy PolyPeptide, a Swiss CDMO, in what is thought to be South Korea's largest biopharma acquisition to date.

News

Manufacturing hangover drives Daiichi Sankyo into the red

Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.

Market Access

pharma commercialisation concept - hcp and laptop and metrics

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.

News

Evotec slashes staff as turnaround plan gathers pace

Evotec has announced the next phase of its company overhaul, dubbed Horizon, that will see 800 people lose their jobs in a bid to cut €75m in costs.

Market Access

Sustaining the mature product portfolio through strategic ou...

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

News

Nick Green, president and CEO of Avid Bioservices

Avid Bioservices to go private in $1.1bn private equity deal

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part

Samsung Biologics agrees $1.81bn takeover of PolyPeptide

Manufacturing hangover drives Daiichi Sankyo into the red

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Evotec slashes staff as turnaround plan gathers pace

Sustaining the mature product portfolio through strategic ou...

Avid Bioservices to go private in $1.1bn private equity deal

Are Makary's priority review vouchers about to be canned?

Securing your ROI: Turning post-acquisition integration into...

outsourcing

Editor's Picks